Your browser is no longer supported. Please, upgrade your browser.
Settings
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.02 Insider Own0.10% Shs Outstand25.99M Perf Week-0.13%
Market Cap1.93B Forward P/E- EPS next Y-5.08 Insider Trans-53.62% Shs Float24.55M Perf Month0.20%
Income-167.00M PEG- EPS next Q-1.56 Inst Own98.70% Short Float14.08% Perf Quarter-1.07%
Sales- P/S- EPS this Y-109.80% Inst Trans-3.64% Short Ratio5.39 Perf Half Y42.04%
Book/sh9.32 P/B7.96 EPS next Y3.10% ROA-67.40% Target Price98.92 Perf Year100.54%
Cash/sh7.70 P/C9.63 EPS next 5Y26.60% ROE-76.80% 52W Range30.95 - 82.68 Perf YTD12.64%
Dividend- P/FCF- EPS past 5Y28.10% ROI- 52W High-10.87% Beta2.49
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low138.09% ATR3.60
Employees57 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)51.20 Volatility3.71% 5.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.40% Profit Margin- Rel Volume0.46 Prev Close74.16
ShortableYes LT Debt/Eq0.00 EarningsMay 22 BMO Payout- Avg Volume641.89K Price73.69
Recom1.90 SMA202.83% SMA50-0.40% SMA20024.20% Volume293,203 Change-0.63%
Mar-27-18Reiterated Chardan Capital Markets Neutral $75 → $100
Feb-21-18Reiterated Needham Strong Buy $81 → $94
Jan-22-18Downgrade Citigroup Buy → Neutral
Jan-18-18Initiated Credit Suisse Outperform $103
Jan-17-18Reiterated UBS Buy $62 → $88
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Dec-14-17Upgrade Needham Buy → Strong Buy $72 → $81
Dec-06-17Reiterated Chardan Capital Markets Neutral $20 → $75
Aug-29-17Initiated Northland Capital Outperform $72
Aug-11-17Resumed BofA/Merrill Neutral
Aug-09-17Upgrade Jefferies Hold → Buy
Jul-11-17Initiated Jefferies Hold
Jun-27-17Reiterated Stifel Buy $45 → $60
Jun-23-17Initiated Deutsche Bank Buy $48
Mar-30-17Upgrade UBS Neutral → Buy $23 → $52
Mar-20-17Upgrade Credit Suisse Underperform → Neutral
Feb-28-17Upgrade Citigroup Neutral → Buy
Feb-23-17Reiterated RBC Capital Mkts Sector Perform $20 → $30
Nov-14-16Downgrade Citigroup Buy → Neutral
Jul-05-16Downgrade WallachBeth Buy → Hold $35
Apr-13-18 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-09-18 07:55AM  Investor Expectations to Drive Momentum within Esperion Therapeutics, Celestica, Sapiens International Corporation N.V, Royal Bank Of Canada, CSS Industries, and SSR Mining Discovering Underlying Factors of Influence GlobeNewswire
Apr-06-18 01:16PM  Biotech Investors Should Consider The Four Horsemen Forbes
Mar-28-18 11:10AM  Heres Whats Moving Esperion And Altimmune, Inc. Market Exclusive
Mar-27-18 09:00PM  Results Renew Optimism for Esperion Therapeutics Motley Fool
09:28AM  Will Esperion Therapeutics Incs (NASDAQ:ESPR) Earnings Grow In The Years Ahead? Simply Wall St.
08:50AM  Esperion's drug clears study as add-on cholesterol treatment Reuters
07:51AM  Esperion's cholesterol drug succeeds in mid-stage study Reuters
07:30AM  Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia GlobeNewswire
Mar-13-18 07:40AM  New Research Coverage Highlights Star Bulk Carriers, IPG Photonics, Mellanox Technologies, Hollysys Automation Technologies, Esperion Therapeutics, and Yirendai Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-12-18 09:16PM  Regeneron Takes Aim at Amgen and Esperion Therapeutics Motley Fool +6.36%
04:53PM  How A Strong Trial From Regeneron Pharma Could Help These Rivals Investor's Business Daily
08:53AM  Regeneron discounts on cholesterol drug sends some rival stocks down MarketWatch
Mar-09-18 07:50AM  Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid ACCESSWIRE
Mar-07-18 04:46PM  Esperion Tanked Despite Strong Cholesterol Drug Trial  Here's Why Investor's Business Daily
04:01PM  Esperion to Participate in Fireside Chat at March 2018 Investor Conferences GlobeNewswire
12:27PM  Has Esperion Therapeutics Inc (NASDAQ:ESPR) Got Enough Cash To Cover Its Short-Term Obligations? Simply Wall St.
11:58AM  After A Two-Decade Quest, Will Esperion's Heart Drug Find A Market? Forbes
08:41AM  Esperion's cholesterol drug succeeds in late-stage study Reuters
08:03AM  UPDATE: Esperion reports positive results in late-stage trial of heart disease treatment , shares jump 4% MarketWatch
07:30AM  Esperion's cholesterol drug succeeds in late-stage study Reuters
07:30AM  Esperion Releases Top Line Results For First Pivotal Phase 3 Study Forbes
07:30AM  Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid GlobeNewswire
Mar-02-18 08:43AM  Is the Options Market Predicting a Spike in Esperion (ESPR) Stock? Zacks
Feb-23-18 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
03:21PM  Esperion Targets $10 a Day for Heart Pill to Undercut Rivals Bloomberg
Feb-20-18 11:25AM  Should You Be Concerned About Esperion Therapeutics Incs (NASDAQ:ESPR) Shareholders? Simply Wall St.
08:09AM  Esperion Therapeutics reports 4Q loss Associated Press
07:30AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-06-18 09:04AM  3 Top Cholesterol Drug Stocks to Consider Buying Now Motley Fool
Jan-22-18 09:58AM  Citi Downgrades Esperion As Hope Of Acquisition Dwindles Benzinga
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-08-18 06:03AM  The 10 Best Stocks of 2017 Motley Fool
Jan-06-18 10:31AM  Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017 Motley Fool
Jan-03-18 04:30PM  Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-14-17 04:30PM  Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors GlobeNewswire
Dec-04-17 09:32AM  3 Stocks That Quadrupled Motley Fool -5.06%
Dec-01-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-17 03:43PM  Esperion Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-13-17 04:30PM  Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference GlobeNewswire
07:30AM  Earnings Review and Free Research Report: Vertexs Revenue Soared 40%; Adjusted EPS Rocketed 212% ACCESSWIRE
Nov-09-17 04:30PM  Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference GlobeNewswire
Nov-07-17 08:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 04:30PM  Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill GlobeNewswire
Oct-10-17 08:30AM  Esperion to Host Analyst and Investor Day Event on October 17 GlobeNewswire
Oct-02-17 04:30PM  Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid GlobeNewswire
Aug-28-17 07:12PM  Cramer Remix: Here's how North Korea's missile could impa... CNBC Videos
06:59PM  Cramer Remix: Here's how North Korea's missile could impact the stock market CNBC
Aug-18-17 07:17AM  These Stocks Have Quadrupled Since Last Year Motley Fool
Aug-14-17 04:30PM  Edited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
11:49AM  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant Zacks
Aug-11-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:05AM  Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure Zacks
Aug-09-17 09:20PM  Esperion Prices Public Offering of Common Stock GlobeNewswire
08:10AM  Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals ACCESSWIRE
Aug-08-17 11:56PM  Esperion Therapeutics reports 2Q loss Associated Press +15.41%
04:32PM  Esperion Announces Proposed Public Offering of Common Stock GlobeNewswire
12:46PM  Here's What's Pushing Up Esperion Therapeutics Inc. Today Motley Fool
08:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results GlobeNewswire
07:30AM  Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin GlobeNewswire
05:20AM  Investor Network: Esperion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 08:59AM  Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings? Zacks
Aug-02-17 04:30PM  Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results GlobeNewswire
Aug-01-17 06:29PM  What to Expect from Epizyme (EPZM) This Earnings Season? Zacks
11:56AM  What's in the Cards for Endo (ENDP) this Earnings Season? Zacks
Jul-26-17 04:30PM  Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor GlobeNewswire
03:59PM  The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug Motley Fool
Jul-21-17 02:42PM  3 Been-There-Done-That Biotech CEOs Who Are Doing it Again Motley Fool
Jul-20-17 09:02PM  3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? Motley Fool +5.63%
Jul-17-17 07:00AM  3 Small Biotech Stocks Being Run by Proven Winners Motley Fool
Jun-30-17 05:46PM  3 Stocks That Turned $7,000 Into As Much As $37,000 So Far in 2017 Motley Fool
Jun-29-17 08:20AM  Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4% Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Heat Biologics Inc. and Esperion Therapeutics Accesswire
Jun-28-17 06:14PM  Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today Zacks +10.38%
04:17PM  Esperion Breaks Out On Cholesterol Tie-Up With Dow's Merck Investor's Business Daily
10:30AM  Esperion's Combo Cholesterol Candidate Enters Phase III Zacks
Jun-26-17 04:05PM  Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe GlobeNewswire
Jun-23-17 09:54AM  Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Benzinga
Jun-22-17 03:42PM  If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool
12:19PM  3 Hot Plays in the Resurgent Biotech Sector Investopedia
Jun-21-17 04:33PM  Biotechs Surge As Generalists Return Amid Subsiding Trump Woes Investor's Business Daily +19.21%
Jun-14-17 04:30PM  Esperion to Present at the JMP Securities 2017 Life Sciences Conference GlobeNewswire
Jun-09-17 01:19PM  Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct TheStreet.com
May-31-17 04:30PM  Esperion to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-22-17 08:05AM  Esperion Provides Update on Common Stock Trading Activity GlobeNewswire
May-19-17 04:30PM  Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference GlobeNewswire -8.14%
May-18-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-12-17 04:30PM  Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference GlobeNewswire
May-08-17 08:00AM  Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics Accesswire
May-06-17 08:01AM  Why Esperion Therapeutics Shares Were Flat In April Motley Fool
May-05-17 05:02AM  Esperion Therapeutics reports 1Q loss Associated Press -5.22%
May-04-17 04:05PM  Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results GlobeNewswire
May-01-17 02:32PM  3 Best Biotech Stocks During Trump's First 100 Days Motley Fool
Apr-28-17 09:21AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
Apr-26-17 05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
Apr-11-17 07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
Apr-10-17 06:51PM  Cramer's lightning round: I may be alone on this, but this e-commerce play is going higher CNBC +7.57%
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Mar-31-17 08:21AM  Could Pfizer Buy Esperion Therapeutics? Motley Fool
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEWTON ROGER SDirectorMar 29Sale73.269,044662,563639,682Mar 29 07:47 PM
NEWTON ROGER SDirectorFeb 07Option Exercise6.9934,651242,210652,334Feb 09 05:47 PM
MAYLEBEN TIMOTHY MPresident & CEOJan 31Option Exercise1.174,5495,32546,163Feb 01 05:29 PM
VITULLO NICOLEDirectorJan 25Sale71.7911,674838,07615,329Jan 26 05:24 PM
VITULLO NICOLEDirectorJan 24Option Exercise6.9971,235497,9331,107,894Jan 26 05:24 PM
JANNEY DANIELDirectorJan 18Option Exercise6.9971,237497,947631,204Jan 22 08:49 PM
Bartram RichardChief Financial OfficerJan 02Option Exercise3.7017,89266,20019,092Jan 03 06:01 PM
GOLDSTEIN DOV A MDDirectorDec 18Option Exercise3.7021,47179,44321,518Dec 20 05:53 PM
VITULLO NICOLEDirectorDec 06Sale53.859,326502,20525,927Dec 08 04:14 PM